White & Case advises Apollomics Inc. on its US$899 million business combination with Maxpro Capital Acquisition Corp.

Press Release
2 min read

Global law firm White & Case LLP has advised Apollomics Inc., a late-stage clinical biopharmaceutical company, on its US$899 million definitive agreement for a business combination with Maxpro Capital Acquisition Corp. The transaction will result in Apollomics becoming a publicly traded company on the Nasdaq Global Market under the ticker symbol "APML."

Apollomics is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company currently has a pipeline of nine drug candidates across multiple programs, six of which are currently in the clinical stage of development.

The cross-disciplinary and cross-jurisdictional White & Case team was led by M&A partner James Hu and IP transaction partner Andres Liivak in New York, and Capital Markets partner Daniel Nussen in Los Angeles.

The team included M&A associates Luisa Muskus in Houston, and Eric Thornton and Shirley Zhang in New York; Capital Markets associates Chad Klitzman in Miami, Jordan Leon in Washington DC, and Guiying Ji in New York; partner Lauren Papenhausen and associate Yanbing Chu in Boston (White Collar); partner Laura McDaniels in Silicon Valley (Employment, Compensation & Benefits); associate Ajita Shukla in Washington, DC (IP); partner F. Paul Pittman in Washington, DC (Cybersecurity); partner Rebecca Farrington and associate Allain Andry in Washington, DC (Antitrust); partner Sang Ji and associate Adriana Zhan in New York (Tax); and partner Maia Gez (US Public Company Advisory). Law clerks Carolina Tiru Vega, Chloe He, Jordan Leon and Patrick Huston assisted on the transaction.

The team received valuable support from partners Alex Zhang (M&A) and Jessica Zhou (Capital Markets) and associate Rita Li (M&A) on China-related matters.

Press contact
For more information please speak to your local media contact.